Cedric Jacqueline

List of Publications by Year
in descending order

71	2,051	236925 25	265206 42
papers	citations	h-index	g-index

74	74	74	2773
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Multifunctional Sactipeptide Ruminococcin C1 Displays Potent Antibacterial Activity In Vivo as Well as Other Beneficial Properties for Human Health. International Journal of Molecular Sciences, 2021, 22, 3253.	4.1	11
2	Efficacy of Nanoencapsulated Daptomycin in an Experimental Methicillin-Resistant Staphylococcus aureus Bone and Joint Infection Model. Antimicrobial Agents and Chemotherapy, 2021, 65, e0076821.	3.2	3
3	Alveolar Macrophages: Adaptation to Their Anatomic Niche during and after Inflammation. Cells, 2021, 10, 2720.	4.1	21
4	Interleukin-22 regulates interferon lambda expression in a mice model of pseudomonas aeruginosa pneumonia. Molecular Immunology, 2020, 118, 52-59.	2.2	15
5	Regulatory T Cells Expressing Tumor Necrosis Factor Receptor Type 2 Play a Major Role in CD4+ T-Cell Impairment During Sepsis. Journal of Infectious Diseases, 2020, 222, 1222-1234.	4.0	13
6	Pseudomonas aeruginosa Infection Impairs NKG2D-Dependent NK Cell Cytotoxicity through Regulatory T-Cell Activation. Infection and Immunity, 2020, 88, .	2.2	3
7	Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis. Nature Immunology, 2020, 21, 636-648.	14.5	128
8	Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent Î²-Lactamâ˜Î²-Lactamase Inhibitor Combination. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	65
9	Immunotherapy With Antiprogrammed Cell Death 1 Antibody Improves Outcome in a Mouse Model of Spinal Cord Injury Followed by Staphylococcus aureus Pneumonia. Critical Care Medicine, 2019, 47, e28-e35.	0.9	2
10	Phosphonic Acid Fluorescent Organic Nanoparticles for High-Contrast and Selective Staining of Gram-Positive Bacteria. ACS Omega, 2018, 3, 17392-17402.	3.5	8
11	Live intramacrophagic Staphylococcus aureus as a potential cause of antibiotic therapy failure: observations in an in vivo mouse model of prosthetic vascular material infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 2418-2421.	3.0	6
12	Interaction of Cutibacterium (â€‰formerly Propionibacterium) acnes with bone cells: a step toward understanding bone and joint infection development. Scientific Reports, 2017, 7, 42918.	3.3	42
13	Interleukin-22 level is negatively correlated with neutrophil recruitment in the lungs in a Pseudomonas aeruginosa pneumonia model. Scientific Reports, 2017, 7, 11010.	3.3	31
14	Immune discrepancies during inÂvitro granuloma formation in response to Cutibacterium (formerly) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.1	5
15	Local Modulation of Antigen-Presenting Cell Development after Resolution of Pneumonia Induces Long-Term Susceptibility to Secondary Infections. Immunity, 2017, 47, 135-147.e5.	14.3	133
16	In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents. Journal of Global Antimicrobial Resistance, 2017, 10, 326-329.	2.2	9
17	Exoenzyme T Plays a Pivotal Role in the IFN-Î³ Production after Pseudomonas Challenge in IL-12 Primed Natural Killer Cells. Frontiers in Immunology, 2017, 8, 1283.	4.8	12
18	Adaptive processes ofStaphylococcus aureusisolates during the progression from acute to chronic bone and joint infections in patients. Cellular Microbiology, 2016, 18, 1405-1414.	2.1	47

#	Article	IF	Citations
19	MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa. Journal of Antibiotics, 2016, 69, 806-810.	2.0	2
20	New Insight into Daptomycin Bioavailability and Localization in Staphylococcus aureus Biofilms by Dynamic Fluorescence Imaging. Antimicrobial Agents and Chemotherapy, 2016, 60, 4983-4990.	3.2	34
21	Newin vitroandin vivomodels to evaluate antibiotic efficacy inStaphylococcus aureusprosthetic vascular graft infection. Journal of Antimicrobial Chemotherapy, 2016, 71, 1291-1299.	3.0	21
22	Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants. European Journal of Clinical Pharmacology, 2015, 71, 611-615.	1.9	15
23	Pathogenic potential ofEscherichia coliclinical strains from orthopedic implant infections towards human osteoblastic cells. Pathogens and Disease, 2015, 73, ftv065.	2.0	45
24	Hydrocortisone Prevents Immunosuppression by Interleukin-10+ Natural Killer Cells After Trauma-Hemorrhage. Critical Care Medicine, 2014, 42, e752-e761.	0.9	36
25	Impact of bacterial biofilm on the treatment of prosthetic joint infections. Journal of Antimicrobial Chemotherapy, 2014, 69, i37-i40.	3.0	136
26	Linezolid Dampens Neutrophil-Mediated Inflammation in Methicillin-Resistant Staphylococcus aureus-Induced Pneumonia and Protects the Lung of Associated Damages. Journal of Infectious Diseases, 2014, 210, 814-823.	4.0	31
27	In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: Comparison with ceftazidime, piperacillin/tazobactam and imipenem. International Journal of Antimicrobial Agents, 2014, 44, 218-221.	2.5	7
28	Depletion of Natural Killer Cells Increases Mice Susceptibility in a Pseudomonas aeruginosa Pneumonia Model*. Critical Care Medicine, 2014, 42, e441-e450.	0.9	42
29	Analysis of Autofluorescence in Polymorphonuclear Neutrophils: A New Tool for Early Infection Diagnosis. PLoS ONE, 2014, 9, e92564.	2.5	18
30	Toll-like receptor-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells. European Respiratory Journal, 2013, 42, 1365-1378.	6.7	22
31	Management of MRSA/GISA, VISA Endocarditis. Current Infectious Disease Reports, 2013, 15, 329-334.	3.0	4
32	A delivery system of linezolid to enhance the MRSA osteomyelitis prognosis: in vivo experimental assessment. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 195-198.	2.9	5
33	Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response. Journal of Antimicrobial Chemotherapy, 2013, 68, 177-183.	3.0	29
34	Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia. Journal of Antimicrobial Chemotherapy, 2012, 67, 780-781.	3.0	2
35	Antenatal Phosphodiesterase 4 Inhibition Restores Postnatal Growth and Pulmonary Development in a Model of Chorioamnionitis in Rabbits. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 620-628.	2.5	2
36	pH-controlled delivery of gentamicin sulfate from orthopedic devices preventing nosocomial infections. Journal of Controlled Release, 2012, 162, 373-381.	9.9	68

#	Article	IF	Citations
37	A new experimental model of acute osteomyelitis due to methicillin-resistant Staphylococcus aureus in rabbit. Letters in Applied Microbiology, 2011, 52, 253-257.	2.2	25
38	Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2011, 66, 863-866.	3.0	38
39	Diffusion of Ofloxacin in the Endocarditis Vegetation Assessed with Synchrotron Radiation UV Fluorescence Microspectrocopy. PLoS ONE, 2011, 6, e19440.	2.5	11
40	CpG-ODN and MPLA Prevent Mortality in a Murine Model of Post-Hemorrhage-Staphyloccocus aureus Pneumonia. PLoS ONE, 2010, 5, e13228.	2.5	34
41	In Vivo Assessment of the Antimicrobial Activity of a Calcium-Deficient Apatite Vancomycin Drug Delivery System in a Methicillin-Resistant Staphylococcus aureus Rabbit Osteomyelitis Experimental Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 950-952.	3.2	10
42	Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model. Journal of Antimicrobial Chemotherapy, 2010, 65, 2264-2265.	3.0	16
43	Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. Journal of Antimicrobial Chemotherapy, 2010, 65, 1749-1752.	3.0	63
44	Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem. Journal of Antimicrobial Chemotherapy, 2010, 65, 2423-2427.	3.0	16
45	Les modÃ¨les expÃ©rimentaux animaux peuvent-ils contribuer Ã la bonne utilisation des antibiotiquesÂ?. Antibiotiques, 2010, 12, 131-135.	0.1	1
46	Influence of the AtlE autolysin on the activity of cell wall-active agents against Staphylococcus epidermidis. International Journal of Antimicrobial Agents, 2010, 35, 204-206.	2.5	3
47	Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. International Journal of Antimicrobial Agents, 2010, 36, 542-544.	2.5	57
48	Fourier Transform Infrared Microspectroscopy of Endocarditis Vegetation. Applied Spectroscopy, 2010, 64, 901-906.	2.2	9
49	Efficacy of Ciprofloxacin in an Experimental Model of Escherichia coli Chorioamnionitis in Rabbits. Antimicrobial Agents and Chemotherapy, 2009, 53, 1624-1627.	3.2	4
50	In Vivo Activity of a Novel Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin, Ceftaroline, against Vancomycin-Susceptible and -Resistant Enterococcus faecalis Strains in a Rabbit Endocarditis Model: a Comparative Study with Linezolid and Vancomycin. Antimicrobial Agents and Chemotherapy, 2009, 53, 5300-5302.	3.2	36
51	In vivo impact of the MexAB-OprM efflux system on Î²-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection. International Journal of Antimicrobial Agents, 2009, 33, 417-420.	2.5	10
52	Internal device decreases antibioticâ€™s efficacy on experimental osteomyelitis. Journal of Children's Orthopaedics, 2008, 2, 239-243.	1.1	10
53	Intermittent active motion versus immobilization in the treatment of Staphylococcus aureus-induced arthritis in a rabbit model. Journal of Children's Orthopaedics, 2008, 2, 491-495.	1.1	7
54	Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model. International Journal of Antimicrobial Agents, 2008, 31, 158-160.	2.5	6

#	Article	IF	Citations
55	In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model. Antimicrobial Agents and Chemotherapy, 2007, 51, 3397-3400.	3.2	112
56	In Vivo Efficacy of Moxifloxacin Compared with Cloxacillin and Vancomycin in a Staphylococcus aureus Rabbit Arthritis Experimental Model. Antimicrobial Agents and Chemotherapy, 2007, 51, 3401-3403.	3.2	5
57	In Vitro and In Vivo Assessment of Linezolid Combined with Ertapenem: a Highly Synergistic Combination against Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2006, 50, 2547-2549.	3.2	32
58	The effects of milrinone on hemodynamics in an experimental septic shock model. Pediatric Critical Care Medicine, 2005, 6, 195-199.	0.5	11
59	Influence of Carbon Dioxide on the MIC of Telithromycin for Streptococcus pneumoniae : an In Vitro - In Vivo Study. Antimicrobial Agents and Chemotherapy, 2005, 49, 464-466.	3.2	6
60	Eagle Effect inCorynebacterium diphtheriae. Journal of Infectious Diseases, 2005, 191, 2118-2120.	4.0	23
61	Activity of Glycopeptides against Staphylococcus aureus Infection in a Rabbit Endocarditis Model: MICs Do Not Predict In Vivo Efficacy. Antimicrobial Agents and Chemotherapy, 2005, 49, 857-859.	3.2	24
62	In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2005, 49, 45-51.	3.2	85
63	In Vitro and In Vivo Bactericidal Activities of Vancomycin Dispersed in Porous Biodegradable Poly(Îµ-Caprolactone) Microparticles. Antimicrobial Agents and Chemotherapy, 2005, 49, 3025-3027.	3.2	26
64	Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. Journal of Antimicrobial Chemotherapy, 2004, 54, 767-771.	3.0	20
65	In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents, 2004, 24, 393-396.	2.5	34
66	In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. Journal of Antimicrobial Chemotherapy, 2003, 51, 857-864.	3.0	109
67	Simulation of Human Gentamicin Pharmacokinetics in an Experimental Enterococcus faecalis Endocarditis Model. Antimicrobial Agents and Chemotherapy, 2003, 47, 3663-3666.	3.2	7
68	Persistent Bacteremia in Rabbit Fetuses despite Maternal Antibiotic Therapy in a Novel Intrauterine-Infection Model. Antimicrobial Agents and Chemotherapy, 2003, 47, 2125-2130.	3.2	7
69	In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model. Antimicrobial Agents and Chemotherapy, 2002, 46, 3706-3711.	3.2	75
70	Combination of Quinupristin-Dalfopristin and Gentamicin against Methicillin-Resistant Staphylococcus aureus : Experimental Rabbit Endocarditis Study. Antimicrobial Agents and Chemotherapy, 2002, 46, 2174-2178.	3.2	25
71	Different Aminoglycoside-Resistant Phenotypes in a Rabbit Staphylococcus aureus Endocarditis Infection Model. Antimicrobial Agents and Chemotherapy, 2002, 46, 1591-1593.	3.2	17